AB-205 is a novel, experimental, cellular therapy intended for treatment of toxicities related to high-dose chemotherapy with or without radiation. AB-205 is composed of endothelial cells genetically modified using the E-CEL® technology.
Clinical Study AB-205-001 (ongoing) is a first-in-human, open-label, non-randomized, safety study of AB-205 in patients with relapsed, chemo-sensitive, non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) who are undergoing high-dose therapy (HDT) and autologous stem cell transplantation (ASCT).
HDT-ASCT is a standard-of-care for relapsed lymphoma, including both NHL and HL. HDT involves the administration of high doses of multiple chemotherapies. In certain circumstances, oncologists prescribe local radiation in addition to HDT. HDT has been proven to be a very effective, curative therapy for high-risk, relapsed lymphoma. However, HDT also produced medically significant bystander effect, whereby multiple tissues and organs are affected, including the bone marrow; the gastrointestinal tract and oral mucosa; the lungs; the kidneys; and other healthy tissues. Following HDT, ASCT (autologous stem cell transplantation, using blood stem cells collected from the patient prior to administration of HDT) is performed to rescue the patient’s marrow and restore the blood and immune system. Because of the bystander effect which causes widespread damages to the vascular niche of multiple healthy tissues and organs, the main recovery mechanism (i.e., organ vascular niches) are disabled, leaving the patient to recovery slowly while experiencing serious side effects (prolonging hospital stay) and profound misery, affecting quality of life. Currently, there is no therapy that addresses the root of the slow recovery (i.e., damage to the vascular niches). Therefore, there is an immediate and substantial need for effective treatments that minimize the severe toxicities related to high-intensity cancer treatments.
AB-205 + HDT-ASCT is being studied in Clinical Study AB-205-001, partnered and co-funded by the California Institute of Regenerative Medicine (CIRM). This ongoing Phase 1 b trial has the following renowned clinical sites involved: Memorial Sloan Kettering Cancer Center (New York City, NY), City of Hope Cancer Center (Duarte, CA), MD Anderson Cancer Center (Houston, TX), Vanberbilt University Medical Center (Nashville, TN) and University of California Davis (Sacramento, CA).
For more information, please visit ClinicalTrials.gov